ReviewWorld journal of oncology2015
Role of Topotecan in Non-Small Cell Lung Cancer: A Review of Literature.
Review in World journal of oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Validating TDP1 as an Inhibition Target for Lipophilic Nucleoside Derivative in Human Cells.International journal of molecular sciences · 2025Article
- Fatty acid binding protein 5 inhibitors as novel anticancer agents against metastatic castration-resistant prostate cancer.Bioorganic & medicinal chemistry · 2025Article
- Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index.Cancers · 2025Review
- Nanomedicine Innovations for Lung Cancer Diagnosis and Therapy.ACS applied materials & interfaces · 2025Review
- In Vivo and Clinical Studies of Natural Products Targeting the Hallmarks of Cancer.Handbook of experimental pharmacology · 2025Review
- Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Effect of safranal on the response of cancer cells to topoisomerase I inhibitors: Does sequence matter?Frontiers in pharmacology · 2022Article
- LncTx: A network-based method to repurpose drugs acting on the survival-related lncRNAs in lung cancer.Computational and structural biotechnology journal · 2021Article
- Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model.Frontiers in cell and developmental biology · 2021Article
- Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line.Frontiers in cell and developmental biology · 2020Article
- Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors.Frontiers in oncology · 2019Article
- TLC388 Induces DNA Damage and G2 Phase Cell Cycle Arrest in Human Non-Small Cell Lung Cancer Cells.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topotecan (TPT), a chemotherapeutic agent, is a topoisomerase-I inhibitor. Topoisomerase-I is a nuclear enzyme that relieves torsion strain in DNA by opening single strand breaks which helps in DNA replication. TPT inhibits this enzyme, thus preventing DNA replication and causes cell death. TPT has demonstrated to have broad spectrum of antitumor activity in tumors like cervical, ovarian, endometrial and small cell lung cancers (SCLCs). The intravenous (IV) formulation of the drug is currently approved by the US Food and Drug Administration for the treatment of patients with SCLC and ovarian cancer at a dose of 1.5 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.